Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.

This study reports the effective use of rFVIIa in covering 20 surgical procedures in 12 patients with hemophilia VIII with high inhibitors, in addition to treating 6 episodes of severe bleeding in 3 patients successfully. All but one of the surgical procedures were insertion or removal of a central venous access device. This paper again proves the efficacy and safety of rFVIIa in treating hemophilia patients with inhibitors.

– M. Aldouri.